Business
Medical Marijuana, Inc. Major Investment AXIM Biotech Files Patent On Controlled Release Chewing Gum To Provide Opioid Addiction Treatment
Medical Marijuana, Inc. Major Investment AXIM Biotech Files Patent On Controlled Release Chewing Gum To Provide Opioid Addiction Treatment.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Major Investment AXIM Biotech Files Patent On Controlled Release Chewing Gum To Provide Opioid Addiction Treatment\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Major Investment AXIM Biotech Files Patent On Controlled Release Chewing Gum To Provide Opioid Addiction Treatment\nPR Newswire\nNEW YORK, June 26, 2017\n\n\n\nNEW YORK, June 26, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC QB: AXIM), a world leader in cannabinoid research and development, filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. The chewing gum may also be used for treatment of chronic pain.\n\n\"We are proud of AXIM Biotech on this milestone achievement that brings the Company one step closer toward entering the $100 billion market in pain management,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"The future of pain medicine may be a high dose of cannabis and a low dose of opioids. Already, we are seeing the incidence of prescription drug overdose death 25% lower in states where medical cannabis is legal, presumably because patients are able to combine natural botanical cannabis and use lower dose opioids to control pain.\"\n\nIn addition, by providing replacement opioids such as opioid agonists and/or antagonists and cannabinoids in a chewing gum form, users may avoid adverse effects caused by injection, smoking and other delivery methods. The act of chewing is also known to be neuroprotective, destressing, it induces the release of reward hormones such as dopamine and serotonin, and improves oral health.\n\nAgonist\n\nAn agonist is a chemical that binds to a receptor and activates the receptor to produce a biolog...